
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DT-001
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Fountain Healthcare Partners
Deal Size : $44.0 million
Deal Type : Series A Financing
Dualyx Raises 40 Million To Progress Treg Therapies For Autoimmune Diseases Into The Clinic
Details : The use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting the highly attractive TNF receptor 2 (TNFR2) and widely regarded as a master control switch in immune modulation, as well as its pipeline of Treg...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 15, 2023
Lead Product(s) : DT-001
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Fountain Healthcare Partners
Deal Size : $44.0 million
Deal Type : Series A Financing
